ACG-721

ACG-721 is an oral small-molecule antibiotic being developed as a potential treatment for pulmonary exacerbations in cystic fibrosis and other orphan infectious diseases. It originated at Arrevus and was acquired, along with Arrevus, by Aceragen to expand its late-stage rare disease pipeline, and is described as a late-stage, orally available therapy intended to address unmet needs in managing infectious complications in cystic fibrosis.[3][4][5] Public information emphasizes its role as a systemic anti-infective for rare pulmonary conditions rather than detailing a specific molecular target, and formal clinical development has focused on cystic fibrosis pulmonary exacerbations as the lead indication.[4][5]